CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
CBLL: A Form 144 excerpt lists multiple reported sales of common stock by David J. Foehr. The excerpt shows sales on 12/03/2025 of 5,265 shares for $88,609.95; on 01/05/2026 of 5,556 shares for $125,565.60; on 02/03/2026 of 5,556 shares for $111,120.00; and on 02/23/2026 of 569 shares for $11,263.07. The excerpt also notes restricted stock vesting on 02/20/2026 for 781 shares identified as compensation.
Insider Form 144 reports multiple dispositions of common stock. The filing lists planned sale/transfer of 705 common shares associated with a 02/20/2026 restricted stock vesting through Fidelity Brokerage Services LLC. It also discloses three recent open-market dispositions by Raymond Woo of 11,112 shares each on 12/01/2025, 01/02/2026, and 02/02/2026 with aggregate proceeds shown per sale.
Xingjuan Chao reported intent to sell 2,084 common shares associated with restricted stock vesting on 02/20/2026. The filing also discloses prior dispositions of 79,000 shares on 01/05/2026 and 39,000 shares on 02/04/2026, with cash amounts shown for each trade.
Scott E. Blumberg reported a sale of common stock. He indicated an intent to sell 808 shares of Common Stock on 02/20/2026 tied to restricted stock vesting as issuer compensation. The filing also records a prior sale of 36,000 shares on 12/22/2025 for $756,000.
David J. Foehr reported sales of Common stock and a proposed resale notice under Rule 144. The filing lists three recent sales: 5,265 shares on 12/03/2025, 5,556 shares on 01/05/2026, and 5,556 shares on 02/03/2026. It also shows a restricted stock vesting event dated 02/20/2026 involving 569 shares and identifies Fidelity Brokerage Services LLC as the broker.
Ceribell, Inc. director Josef Parvizi, through the Josef Parvizi Trust, sold 16,714 shares of common stock in open-market transactions on February 19, 2026 under a Rule 10b5-1 trading plan adopted on August 18, 2025.
The weighted average sale price was $20.27 per share, with individual trades between $20.00 and $20.77. Following the sale, the Josef Parvizi Trust held 722,652 shares. Separate Innovation ACP Trust and ACP 2021 Trust holdings were 907,911 and 369,088 shares, respectively, where Parvizi is a co-trustee and may be deemed to share beneficial ownership but disclaims it except to the extent of his pecuniary interest.
Ceribell, Inc. director Josef Parvizi reported automatic sales of common stock through trusts associated with him. A total of 8,286 shares were sold in open-market transactions at a weighted average price of about $20 per share under a Rule 10b5-1 trading plan adopted on August 18, 2025. The Josef Parvizi Trust now holds 739,366 shares indirectly, while the Innovation ACP Trust and ACP 2021 Trust hold 907,911 and 369,088 shares indirectly, respectively.
Josef Parvizi Trust reported sales of Common stock under Form 144. The trust reported multiple dispositions: 12/08/2025 sale of 25,000 shares for $506,467.06; 12/15/2025 sale of 25,000 shares for $538,650.34; 01/15/2026 sale of 25,000 shares for $573,453.07; 02/17/2026 sale of 1,300 shares for $26,000.00; and 02/18/2026 sale of 6,986 shares for $139,769.82.
Josef Parvizi Trust submitted a Form 144 reporting proposed sales of common stock. The trust lists 6,986 common shares described as Pre-IPO Shares dated 08/29/2014 issued as compensation. The filing also records recent executed dispositions: 25,000 shares on 12/08/2025 for $506,467.06, 25,000 shares on 12/15/2025 for $538,650.34, 25,000 shares on 01/15/2026 for $573,453.07, and 1,300 shares on 02/17/2026 for $26,000.00. Timing and method of any future sales are not specified in this excerpt.